EE260 Cost-Effectiveness Analysis of Sacituzumab Govitecan As Second-Line Treatment for Metastatic Triple-Negative Breast Cancer in Japan
Jun 1, 2023, 00:00 AM
10.1016/j.jval.2023.03.561
https://www.valueinhealthjournal.com/article/S1098-3015(23)00661-7/fulltext
Section Title :
Section Order :
10043
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00661-7&doi=10.1016/j.jval.2023.03.561